Logo image of BJDX

BLUEJAY DIAGNOSTICS INC (BJDX) Stock Fundamental Analysis

USA - NASDAQ:BJDX - US0956335097 - Common Stock

1.57 USD
-0.02 (-1.26%)
Last: 11/7/2025, 8:00:02 PM
1.58 USD
+0.01 (+0.64%)
After Hours: 11/7/2025, 8:00:02 PM
Fundamental Rating

2

BJDX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of BJDX is average, but there are quite some concerns on its profitability. BJDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year BJDX has reported negative net income.
In the past year BJDX has reported a negative cash flow from operations.
In the past 5 years BJDX always reported negative net income.
In the past 5 years BJDX always reported negative operating cash flow.
BJDX Yearly Net Income VS EBIT VS OCF VS FCFBJDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of BJDX (-311.68%) is worse than 96.83% of its industry peers.
The Return On Equity of BJDX (-377.26%) is worse than 79.89% of its industry peers.
Industry RankSector Rank
ROA -311.68%
ROE -377.26%
ROIC N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BJDX Yearly ROA, ROE, ROICBJDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

BJDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BJDX Yearly Profit, Operating, Gross MarginsBJDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

5

2. Health

2.1 Basic Checks

BJDX has more shares outstanding than it did 1 year ago.
BJDX has less shares outstanding than it did 5 years ago.
BJDX has a better debt/assets ratio than last year.
BJDX Yearly Shares OutstandingBJDX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
BJDX Yearly Total Debt VS Total AssetsBJDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

BJDX has an Altman-Z score of -9.77. This is a bad value and indicates that BJDX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.77, BJDX is doing worse than 76.72% of the companies in the same industry.
BJDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BJDX (0.00) is better than 74.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.77
ROIC/WACCN/A
WACCN/A
BJDX Yearly LT Debt VS Equity VS FCFBJDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 4.56 indicates that BJDX has no problem at all paying its short term obligations.
The Current ratio of BJDX (4.56) is better than 74.07% of its industry peers.
A Quick Ratio of 4.56 indicates that BJDX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.56, BJDX belongs to the best of the industry, outperforming 80.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.56
Quick Ratio 4.56
BJDX Yearly Current Assets VS Current LiabilitesBJDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.11% over the past year.
EPS 1Y (TTM)97.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BJDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BJDX Yearly Revenue VS EstimatesBJDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2025 2026 2M 4M 6M 8M
BJDX Yearly EPS VS EstimatesBJDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

1

4. Valuation

4.1 Price/Earnings Ratio

BJDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BJDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BJDX Price Earnings VS Forward Price EarningsBJDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BJDX Per share dataBJDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

BJDX's earnings are expected to grow with 30.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.65%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BJDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BLUEJAY DIAGNOSTICS INC

NASDAQ:BJDX (11/7/2025, 8:00:02 PM)

After market: 1.58 +0.01 (+0.64%)

1.57

-0.02 (-1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)N/A N/A
Inst Owners7.37%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap2.62M
Revenue(TTM)N/A
Net Income(TTM)-19.96M
Analysts43.33
Price TargetN/A
Short Float %25.67%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-40.34
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS0
BVpS3.17
TBVpS3.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -311.68%
ROE -377.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.56
Quick Ratio 4.56
Altman-Z -9.77
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)331.42%
Cap/Depr(5y)201.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.45%
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.76%
OCF growth 3YN/A
OCF growth 5YN/A

BLUEJAY DIAGNOSTICS INC / BJDX FAQ

What is the ChartMill fundamental rating of BLUEJAY DIAGNOSTICS INC (BJDX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BJDX.


What is the valuation status for BJDX stock?

ChartMill assigns a valuation rating of 1 / 10 to BLUEJAY DIAGNOSTICS INC (BJDX). This can be considered as Overvalued.


How profitable is BLUEJAY DIAGNOSTICS INC (BJDX) stock?

BLUEJAY DIAGNOSTICS INC (BJDX) has a profitability rating of 0 / 10.


How financially healthy is BLUEJAY DIAGNOSTICS INC?

The financial health rating of BLUEJAY DIAGNOSTICS INC (BJDX) is 5 / 10.


What is the earnings growth outlook for BLUEJAY DIAGNOSTICS INC?

The Earnings per Share (EPS) of BLUEJAY DIAGNOSTICS INC (BJDX) is expected to grow by 67.68% in the next year.